Section 232 Pharmaceutical Duties: Filing Guide

Section 232 pharmaceutical duties create a demanding classification and entry-filing challenge for importers and customs brokers. Every covered shipment requires the correct Chapter 99 heading, including products receiving a 0% rate, while the unusually high default treatment makes classification controls and drawback planning financially significant.

Scope, Effective Dates, and Entry Applicability

The September 29 Expansion Changes the Filing Baseline

The pharmaceutical measures generally cover designated pharmaceutical articles and associated ingredients classified in Chapters 29 and 30 of the HTSUS. Filing is performed through headings 9903.04.60 through 9903.04.70, with the appropriate heading determined by factors such as patent status, origin, intended use, company commitments, product category, and U.S. content.

The first effective date was 12:01 a.m. Eastern Time on July 31, 2026, for products of companies identified in Annex III. At 12:01 a.m. Eastern Time on September 29, 2026, the measures expanded to covered products of all other companies. The date of entry for consumption, or withdrawal from warehouse for consumption, generally controls. There is no broad in-transit exception that allows merchandise shipped before the effective date to avoid the applicable treatment.

HTSUS 9903.04.61, which previously addressed qualifying goods during the interim period, is no longer effective for merchandise entered after 12:01 a.m. on September 29, 2026. Brokers should therefore ensure that post-effective-date entry templates, client instructions, and classification databases do not continue to default to that heading.

The framework applies to covered imports from all countries, but country-specific treatment may change the applicable rate. U.S.-origin pharmaceutical products are not subject to the proclamation tariffs. That exclusion makes origin substantiation especially important where active pharmaceutical ingredients, finished dosage products, or intermediate processing involve multiple jurisdictions.

If a product qualifies for more than one rate under Proclamation 11020, the lowest applicable rate governs. Importers should document every potentially applicable provision rather than stopping after identifying the first plausible Chapter 99 heading.

HTSUS 9903.04.60-9903.04.70 Filing Framework

Selecting the Correct Chapter 99 Heading

The Chapter 99 determination should be made through a controlled decision process. A broker generally needs the ordinary Chapter 29 or 30 classification, country of origin, patent or generic status, manufacturer and company information, intended use, onshoring-plan status, pricing-agreement status, and any facts supporting a specialty or non-commercial provision.

The headings and stated tariff treatments are summarized below:

A 0% outcome does not eliminate the Chapter 99 reporting obligation. The applicable heading still communicates why the covered merchandise receives zero-duty treatment. Omitting that line can create entry errors even when no Section 232 payment is due.

Importers should not infer eligibility for 9903.04.66 from a general description of specialty use or origin. The product, use, and jurisdiction must satisfy the specific eligibility criteria. Likewise, a clinical or research shipment should be supported by records showing that its actual application is non-commercial and consistent with the requirements for 9903.04.70.

Preference Programs, Chapter 98, and FTZ Treatment

Additional Tariffs Require Layered Entry Analysis

Free trade agreement eligibility and other special tariff treatment do not generally displace the pharmaceutical measures. Duties under headings 9903.04.60 through 9903.04.68 are collected in addition to otherwise applicable special rates where relevant. Entry teams should calculate the ordinary tariff treatment and the Section 232 treatment as distinct but related parts of the declaration.

Chapter 98 claims generally remain available when their requirements are satisfied. They cannot, however, be used as a vehicle to circumvent the pharmaceutical duties. Other Chapter 99 provisions likewise should not be assumed to override Proclamation 11020 unless the tariff instructions expressly support that result.

Foreign-Trade Zone Admissions Need Special Controls

Covered pharmaceutical products admitted to a U.S. foreign-trade zone on or after the applicable effective date generally must be admitted in privileged foreign status unless they qualify for domestic status. Privileged foreign status preserves the applicable tariff classification and duty treatment at admission, which can materially affect the duty calculation when merchandise later enters U.S. commerce.

FTZ operators, importers, and brokers should align admission procedures with the Chapter 99 analysis before goods arrive at the zone. A discrepancy between the admission record, commercial documentation, and subsequent consumption entry can complicate both tariff treatment and future drawback analysis.

A practical control framework should connect purchase-order data, product master records, patent or generic status, origin documentation, intended-use certifications, and zone admissions. Time-limited provisions also require automated or calendar-based review. The April 2, 2030 increase for 9903.04.64 and the January 20, 2029 expiration of 9903.04.65 should not remain buried in static classification notes.

For unresolved Section 232 entry-filing questions, trade professionals may contact the Trade Remedy Branch at TradeRemedy@cbp.dhs.gov. Technical transmission issues may generally be directed to the ACE Help Desk.

Pharmaceutical Duty Drawback Opportunities

Proclamation Duties Are Expressly Drawback-Eligible

Drawback is available for duties imposed under Proclamation 11020. This treatment is particularly important because certain other Section 232 measures have restricted or barred drawback, while the pharmaceutical proclamation expressly permits recovery. For products entered under a high-duty heading, the potential refund can materially affect sourcing, export, destruction, and inventory decisions.

Importers and brokers should evaluate drawback at the time of entry rather than waiting until exports occur. The entry record must identify the correct Chapter 99 line and deposited duties, while downstream records must support the relationship between imported merchandise and the exported, destroyed, or manufactured article. The applicable drawback pathway will typically depend on the facts, including whether the claimant uses unused merchandise, substitution, or manufacturing drawback.

Recovery Begins With Reliable Data

A pharmaceutical drawback review should generally capture:

• Import entry numbers, line numbers, dates, quantities, values, and deposited duties
• Ordinary HTSUS and Chapter 99 classifications
• Product identifiers, lot or batch information, and inventory movements
• Export records and proof of exportation
• Destruction records where applicable
• Manufacturing records when imported merchandise is used in production
• Certificates, assignments, and other documents required for the selected claim structure

Classification corrections should be addressed early. An entry reported under the wrong Chapter 99 heading may have an overstated or understated duty amount, and the drawback claim cannot be evaluated accurately until the underlying entry treatment is understood.

The explicit availability of drawback also creates a planning opportunity for importers that export finished pharmaceuticals, transfer imported ingredients into exported production, or destroy eligible merchandise under controlled procedures. Companies should model potential recovery against administrative effort, filing deadlines, record quality, and the risk of duplicate recovery. Brokers can add significant value by connecting entry-filing controls with the client’s export and inventory data before recoverable duties become difficult to trace.

Frequently Asked Questions

Are All Pharmaceutical Imports Subject to a 100% Duty?

No. The 100% combined treatment under 9903.04.60 is the default for covered patented pharmaceutical articles that do not qualify for a more specific provision. Several headings provide 15%, 20%, or 0% treatment based on origin, product status, intended use, onshoring commitments, pricing agreements, or other qualifying facts. If multiple rates apply under the proclamation, the lowest applicable rate governs.

Must an Importer Report a Chapter 99 Heading When the Rate Is 0%?

Yes. Covered merchandise generally requires an applicable heading within 9903.04.60 through 9903.04.70 even when that heading produces a 0% result. The Chapter 99 line establishes the legal basis for the treatment. A zero rate should not be treated as an exemption from reporting.

Is HTSUS 9903.04.61 Still Available?

Not for goods entered after 12:01 a.m. Eastern Time on September 29, 2026. Brokers should remove the interim heading from post-effective-date defaults and determine which of the remaining headings applies to each covered product.

Are U.S.-Origin Pharmaceutical Products Subject to These Duties?

U.S.-origin pharmaceutical products are not subject to the proclamation tariffs. Importers should maintain adequate origin records, particularly when ingredients, processing, packaging, and finished dosage operations occur in different countries.

Can Section 232 Pharmaceutical Duties Be Recovered Through Drawback?

Yes. Duties imposed under Proclamation 11020 are expressly eligible for drawback. Actual recovery depends on the applicable drawback provision, timely filing, export or destruction activity, merchandise eligibility, and supporting records. Importers should review high-duty entries promptly to preserve relevant data and identify potential claims.

Do Free Trade Agreement Rates Eliminate the Section 232 Duty?

Generally, no. Duties under 9903.04.60 through 9903.04.68 are collected in addition to applicable special rates. A preference claim may reduce the ordinary duty while leaving the applicable Section 232 treatment in place. The complete entry calculation should account for both layers.

How Stable Software Can Help

Give Brokers Control of Pharmaceutical Drawback

The express availability of drawback for Section 232 pharmaceutical duties creates a meaningful recovery opportunity, particularly for entries receiving high-duty treatment. Customs brokers need a scalable way to serve importer clients without surrendering control of the filing relationship or giving up a percentage of the refund.

DrawbackAI is Stable Software’s flat-license duty drawback software for U.S. customs brokers. Brokers can white-label the software for importer clients and file claims under their own filer code. Stable Software charges a flat software license and never takes a percentage of the refund. Brokers evaluating pharmaceutical drawback programs can use this model to retain the client relationship while building duty recovery into their broader customs and trade compliance services.

Resources